Maravai LifeSciences Announces Completion of Planned CEO Leadership Transition
28 July 2023 - 6:05AM
Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”)
(NASDAQ: MRVI), a global provider of life science reagents and
services to researchers and biotech innovators, announced that
William “Trey” Martin, III has assumed the role of Chief Executive
Officer (CEO) of Maravai LifeSciences effective July 27, 2023,
consistent with the Company’s previously announced CEO succession
plan. Carl Hull, Maravai’s co-founder and prior interim CEO, will
continue to serve as Maravai’s Executive Chairman of the Board.
“We are thrilled to have Trey step into the role of CEO at
Maravai. Trey is a remarkable leader with strong cultural values,
an impressive career in nucleic acid synthesis, and an extensive
history of operating success. Over the past seven months, he had
the unique opportunity to focus on Maravai’s Biologics Safety
Testing segment and understand the business on a very deep level,
enabling him to further build on his already significant industry
knowledge,” said Carl Hull, Executive Chairman of Maravai. “We
remain extraordinarily confident in Trey’s leadership capabilities
and believe his innate passion for the field will enable him to
drive Maravai’s growth strategy going forward.”
“Maravai means miracle, and I am honored to take the reins as
Maravai’s next CEO and continue to deliver on our mission to enable
the miracles of science at this critical and exciting time in our
industry,” Martin said. “I am grateful to Carl for his leadership
and impact. I look forward to furthering his vision for the company
and appreciate the Board’s trust in me to help realize Maravai’s
bright future.”
Mr. Martin has more than 25 years of executive leadership
experience in life sciences operations, engineering, sales, product
development and marketing. Since December 2022, Mr. Martin has
served as President, Biologics Safety Testing at Maravai. Prior to
that, he was most recently Senior Vice President, Genomic
Medicines, at Danaher Corporation. Mr. Martin originally joined
Danaher with the acquisition of Integrated DNA Technologies (IDT)
in 2018 and served as President of the IDT business there for over
three years. Prior to its acquisition, Mr. Martin held positions of
increasing responsibility over more than two decades at IDT, and
contributed to the consistent growth and competitiveness of the
company’s genomic solutions business through organic and inorganic
growth investments. Mr. Martin holds a Bachelor’s in biochemistry
from the University of Iowa.
About Maravai Maravai is a leading life
sciences company providing critical products to enable the
development of drug therapies, diagnostics, and novel vaccines and
to support research on human diseases. Maravai’s companies are
leaders in providing products and services in the fields of nucleic
acid synthesis and biologics safety testing to many of the world's
leading biopharmaceutical, vaccine, diagnostics and cell and gene
therapies companies.
Forward-looking Statements This press release
may contain "forward-looking statements" within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. Investors are cautioned that statements in this
press release which are not strictly historical statements
constitute forward-looking statements, including, without
limitation, statements related to the expectation that Mr. Martin
will drive Maravai’s growth strategy, constitute forward-looking
statements identified by words like “plan,” “will,” “expect,”
“may,” “anticipate,” or “could” and similar expressions. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including, without limitation, continued
demand for our COVID-19 related products and services, which
currently comprise a significant portion of our revenue, and the
other risks and uncertainties described in greater detail in the
“Risk Factors” section of our most recent Annual Report on Form
10-K and other filings with the U.S. Securities and Exchange
Commission. Actual results may differ materially from those
contemplated by these forward-looking statements, and therefore you
should not rely upon them. These forward-looking statements reflect
our current views and we do not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date hereof except as
required by law.
Contact Information:
Investor Contact: Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
ir@maravai.com
Media Contact: Sara Michelmore
MacDougall Advisors
+1 781-235-3060
maravai@macdougall.bio
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Apr 2024 to May 2024
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From May 2023 to May 2024